Summary & Overview
Wound Debridement and Skin Graft Except Hand for Musculoskeletal and Connective Tissue Disorders with CC: Inpatient Reimbursement Overview
DRG 464 includes inpatient admissions for wound debridement and skin graft procedures, excluding hand operations, associated with musculoskeletal and connective tissue disorders with a Complication or Comorbidity. This grouping matters for inpatient reimbursement because it aligns payment to clinical complexity, procedure intensity, and documented comorbid conditions under Medicare’s inpatient prospective payment system.
DRG 464 Overview
DRG 464 covers inpatient cases involving wound debridement and skin graft procedures, excluding hand procedures, when related to musculoskeletal and connective tissue disorders and coded with a Complication or Comorbidity. This Diagnosis-Related Group groups clinically similar surgical wound care cases for Medicare payment and affects hospital reimbursement by reflecting procedure intensity, resource use, and comorbidity burden. Accurate surgical, wound, and comorbidity coding determines grouping and payment impact. Proper documentation of the diagnosis, procedures, and Complication or Comorbidity supports appropriate inpatient classification.
Clinical Trials
- Acute operative and perioperative randomized trials assessing optimal debridement techniques and graft materials for patients with musculoskeletal and connective tissue disorders who require wound excision and split-thickness or full-thickness skin grafting. These studies enroll adult inpatients with infected, nonhealing, or traumatic wounds overlying joints or soft-tissue defects related to underlying musculoskeletal pathology and compare outcomes such as graft take, time to wound closure, intraoperative blood loss, and short-term complication rates. Results are directly relevant to surgeons, hospital utilization managers, and payers because they inform choices that affect length of stay, resource intensity in the operating room, and immediate postoperative complication costs captured under this DRG.
- Comparative effectiveness studies evaluating adjunctive intraoperative and inpatient therapies (for example, use of negative-pressure wound therapy, biologic dressings, or antimicrobial stewardship strategies) to reduce infection, reoperation, and readmission in patients with connective tissue or musculoskeletal disease-related wounds who receive debridement and grafting. These cohort or pragmatic randomized studies typically enroll medically complex inpatients, including those with diabetes, peripheral vascular disease, or immunosuppression, and measure outcomes such as surgical site infection, need for repeat debridement, antibiotic exposure, and hospital resource utilization. Findings help providers and payers identify interventions that improve clinical outcomes while potentially lowering costs from complications, repeat procedures, and extended inpatient care billed under this DRG.
- Post-discharge outcomes and health services research tracking functional recovery, long-term wound durability, and downstream utilization after inpatient debridement and skin grafting for musculoskeletal/connective tissue disorders. These longitudinal observational studies follow patients after discharge to assess readmissions, outpatient wound care needs, rehabilitation needs, prosthetic or orthotic use, and overall return-to-function, stratified by comorbidity and index-procedure characteristics. This research is important for payers and discharge planners because it quantifies post-acute care needs and costs beyond the initial DRG payment window and can guide bundled payment models, care pathway design, and allocation of home health or outpatient resources.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.